Semaglutide formulation is a diabetes drug. It was analyzed using PROTEIN KW-802.5, an aqueous SEC (GFC) column.
Sample: 5 µL
- 1.Semaglutide formulation 1.5 mg/mL
- Column
- ：Shodex PROTEIN KW-802.5 (8.0 mm I.D. x 300 mm)
- Eluent
- ：H2O/CH3CN/TFA=500/500/1
- Flow rate
- ：0.5 mL/min
- Detector
- ：UV (280 nm)
- Column temp.
- ：30 ℃
Sample Name Index
Operation Manual / Certificate of Analysis
Operation Manuals and Certificate of Analysis / Inspection Certificate for the following products can be downloaded here.
Product Name Index
Applications
- Basic Drugs : Under Neutral Condition
- Basic Drugs : Effects of Eluent pH
- Basic Drugs : Effects of Ion Concentration
- Effects of pH of Eluent on Elution Volume and Plate Number (ODP-50 4D)
- Antifebriles (1) (DS-613)
- Antifebriles (2) (DM-614)
- Antipyretic Analgesics (ODP-50 4D)
- Diuretics (1) (ODP-50 4D)
- Diuretics (2) (DE-613)
- Anti Cancer Drugs (ODP-50 4D)
- Drugs (ODP-50 4D)
- Anti Inflammatory Drugs (1) (ODP-50 4E)
- Anti Inflammatory Drugs (2) (ODP-50 4E)
- Scopolamine and Atropine
- Tetracaine (ODP-50 4D)
- Procainamides (1) (DE-613)
- Procainamides (2) (DE-413)
- Procaine and Procaineamide (ODP-50 4D)
- Methylxantines (1) (DS-613)
- Methylxantines (2)
- Local Anesthetics (1) (ODP-50 4D)
- Local Anesthetics (2) (DE-413)
- Cinchona Alkaloids
- Antibiotics (1) (ODP-50 4D)
- Antibiotics (2) (DE-413)
- Sulfanilamides (DE-413)
- Barbiturates (ODP-50 4D)
- Effects of pH of Eluent on Sensitivity of Barbital
- Berberine in Japanese Goldthread (ODP-50 4D)
- Glycyrrhizin in Licorice (ODP-50 6D)
- Saikosaponins (ODP-50 6D)
- Soyasaponin in Soy Bean (DS-613)
- Curative Drugs to Eradicate H.Pyrori (JJ-50 2D)
- Enalapril Maleate (DS-413)
- Tetracycline Derivative Antibiotics (ODP-40 4D)
- Short Amines (ODP2 HP)
- Ginsenoside (Ginseng Saponin) (DS-413)
- Ginsenoside (Carrot Saponin) (NH2P-50 4E)
- Analysis of Macrolide Antibiotics and Derivatives (ODP-50 4D)
- Ribavirin (KS-801)
- Anti-diabetes Drugs (NH2P-50 4E)
- LC/MS/MS Analysis of Oral Anti-diabetes Drugs (VC-50 2D)
- Characterization of Polymeric Excipients by SEC-IR (SB-806M HQ)
- Simultaneous Analysis of Multi Symptom Cold Formula (ODP2 HP)
- LC/MS Analysis of Statins (ODP2 HP-2B)
- LC/MS Analysis of Metformin (NH2P-40 2D)
- Separation of Gingerol and Shogaol (C18M 4D)
- Bibliographic Information for Analysis of Conjugate Vaccine
- LC/MS/MS Analysis of Organic Sulfonic Acids (VT-50 2D)
- Analysis of Allantoin in a Commercial Disinfectant (VG-50 4E)
- LC/MS Analysis of Aminoglycoside Antibiotics (VC-50 2D)
- LC/MS/MS Analysis of Ribavirin (VC-50 2D)
- LC/MS/MS Analysis of Salacia Extract (1) (VC-50 2D)
- LC/MS/MS Analysis of Salacia Extract (2) (VT-50 2D)
- Comparison of Analysis of Glucosamine Hydrochloride between Polymer-based Amino Columns and Silica-based Amino Columns
- LC/MS Analysis of Streptomycins (VC-50 2D)
- LC/MS/MS Analysis of Citicoline (VT-50 2D)
- SEC Analysis of Liraglutide Formulation (KW-802.5)
- SEC Analysis of Antibody Drug Conjugate (LW-803)
- SEC Analysis of Saccharated Ferric Oxide Injection (SB-804 HQ + SB-802.5 HQ)
- Analysis of α-GPC in Supplements (NH2P-50 4E)
- SEC Analysis of Rituximab (LW-803)
- Analysis of Trypsin-Digested Rituximab (C18U 2D)
- PEG-Chymotrypsin (KW-802.5)
- SEC Analysis of PEG-Asparaginase (SB-806 HQ)
- LC/MS Analysis of Macrolide Antibiotics (C18U 2B)
- SEC Analysis of Filgrastim (KW-803)
- Analysis of Levocarnitine (NH2P-50 4E)
- Analysis of Inositol According to Japanese Pharmaceutical Excipients 2018 (KS-801)
- Analysis of Sodium Risedronate (IC I-524A)
- Analysis of Ibandronate Sodium (I-524A)
- Analysis of Zoledronic Acid (IC I-524A)
- Separation of Fosfomycin and its Thermal Decomposition Products (NH2P-50 4E)
- Analysis of Ferric Carboxymaltose (SB-804 HQ + SB-802.5 HQ)
- Quantitative Analysis of Sucrose in Saccharated Iron Oxide Injection (VG-50 4E)
- Analysis of Carboplatin (NH2P-50 4E)
- Separation of Ceftazidime and Arginine (KW402.5-4F)
- Analysis of Sorbitol in Nicardipine Hydrochloride Injection (NH2P-50 4E)
- SEC Analysis of Etelcalcetide Hydrochloride (KW-802.5)